#1ResMed Investor Presentation Q3 2019 May 2, 2019#2Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. ©2019 ResMed I Q3 2019 Investor Presentation | 2 ResMed#3Overview © 2019 ResMed I Q3 2019 Investor Presentation | 3 ResMed#4Who we are / what we do • Listed on NYSE & ASX, -$15B market cap World-leading connected health company with more than 9 million 100% cloud-connectable devices - More than 10 million patients in AirView monitoring ecosystem Nearly 80 million patient accounts in out-of-hospital care network Innovative designer and manufacturer of award-winning devices and cloud-based software solutions - Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs Cloud-based software health applications and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers Tools that allow fewer people to manage more patients Empower patients to track own health outcomes © 2019 ResMed | Q3 2019 Investor Presentation | 4 85 Fit pekes Excelsanded 2 ResMed ResMed#5Why invest? driving long-term shareholder value لحا • Market Dynamics Underpenetrated markets in sleep & COPD • Healthcare costs continue to increase • Focus on improving patient outcomes Value-based technology solutions. Growth & Innovation • Global leader in connected health for sleep and respiratory care Long-term growth opportunities 5,500+ patents and designs¹ • ~ 7-8% of revenue invested in R&D Financial Results • Historical revenue and profit growth • Recurring revenue • • Operating excellence program Strong track record of disciplined capital deployment 1. Pending and issued patents and designs as of 3/31/2019 ©2019 ResMed I Q3 2019 Investor Presentation | 5 ResMed#6MACRO MICRO Key demographic, political, and healthcare trends present multiple opportunities for ResMed Delivering the correct care when needed Healthcare continues to rise in importance as a major topic on social and political agendas around the world. Increasing Chronic Disease Burden ©2019 ResMed I Q3 2019 Investor Presentation | 6 00000000 Aging Population Healthcare Costs Growing Physician Shortages The shift to value-based healthcare and consumerization-of-care is here to stay. Healthcare System Pain Points Delivering care in lower cost settings Patient Engagement Documentation Data Availability Communication Analytics Integration of Data & Technology is key to driving increased awareness & treatment ResMed#7> ResMed's 2025 strategy ResMed 2025 250 million lives improved in out-of-hospital healthcare. in 2025! Purpose Empower people to live healthier and higher quality lives in the comfort of their home Growth Focus Growth Advantage Global health epidemics in sleep apnea, COPD, other major chronic conditions, and caring for patients with SaaS solutions in the out-of-hospital setting Transform patient care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences and efficiency Growth Foundations High-performing, diverse and entrepreneurial people Industry-leading innovation and business excellence Digital health technology leadership in our markets © 2019 ResMed | Q3 2019 Investor Presentation | 7 ResMed#8Our Business - Sleep ©2019 ResMed I Q3 2019 Investor Presentation | 8 ResMed#9Sleep business strategy Deliver a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes OPTIMIZE EFFICIENCIES FOR PROVIDERS Home medical equipment / home care provider-facing solutions that drive workflow efficiencies Long-term adherence solutions that improve patient management and meet the needs of referring physicians A DELIVER BEST-IN-CLASS PATIENT EXPERIENCE Patient-facing solutions, from identification to treatment, that streamline the experience and improve long-term adherence EMBRACE AND ENABLE INTEGRATED CARE MODELS Payer-facing solutions that enable population management, backed by our data insights, outcomes research, and market access Collaboration - Operating Excellence - Lean Innovation - High Performance Culture – Talent ©2019 ResMed I Q3 2019 Investor Presentation | 9 ResMed#10What is sleep-disordered breathing? • · Abnormal respiration during sleep - the cessation of breathing or "sleep suffocation" Most prevalent is obstructive sleep apnea - collapse of the upper airway despite ongoing effort Other types include central sleep apnea -- lack of breathing and lack of effort and mixed apnea -- Normal airway Partially obstructed airway Obstructed airway Arousal © 2019 ResMed I Q3 2019 Investor Presentation | 10 ResMed#11Global prevalence of obstructive sleep apnea (OSA) presents opportunity to drive increased awareness United States AHI≥5 = 54 M AHI≥15 24 M Brazil AHI≥5 49 M AHI≥15 25 M Benjafield, et al. AJRCCM 2018 (abstract) ©2019 ResMed I Q3 2019 Investor Presentation | 11 France AHI≥5 = 24 M AHI≥15 = 12 M Germany AHI≥5 = 26 M AHI≥15 14 M China Nigeria AHI≥5 = 31 M AHI≥1512 M Pakistan AHI≥5 = 176 M AHI≥15 = 66 M AHI≥5 = 42 M AHI≥15 17 M India AHI≥5 52 M 2M AHI≥15 29 M AHI ≥ 5 936,360,689 AHI ≥ 15 424,630,028 Russian Federation AHI≥5 = 40 M AHI≥15 = 20 M Japan AHI≥5 22 M AHI≥15 9 M ResMed#12Sleep apnea is more than 80% undiagnosed For every 100 U.S. adults... 4 KNOW THEY HAVE SLEEP APNEA¹² 1 Peppard PE et al. Am J Epidemiol 2013 2 Young T et al. Sleep 1997 ©2019 ResMed I Q3 2019 Investor Presentation | 12 22 DON'T KNOW THEY HAVE IT¹.2 ResMed#13Sleep apnea is prevalent in other chronic conditions Stroke 62% Highly prevalent in key chronic diseases Type 2 Diabetes 72% Morbid Obesity 77% Atrial Fibrillation 49% Heart Failure 76% Drug-Resistant Hypertension 83% References: Gami AS et al. Circulation 2004, O'Keefe and Patterson, Obes Surgery 2004, Logan et al. J. Hypertension 2001, O'Keeffe T and Patterson EJ. Obes D et al. Endocr Pract 2007, Bassetti C and Aldrich M. Sleep 1999 ©2019 ResMed I Q3 2019 Investor Presentation | 13 Surg 2004, Einhorn ResMed#14Transforming the treatment & management of sleep apnea Quiet AirSense TM 10 AirSense TM10 Auto Set for Her AirCurve TM 10 Comfortable Compact AirMini™ 90 ResMed Connected ர AirFit P10 Nasal Pillows System S AirFit P30i Nasal pillows mask AirFit N20 Nasal mask AirFit™ F20 Full face mask AirFit™ N30 Nasal cradle mask AirFit™ F30 -ull face mask AirView TM brightree® 85 ©2019 ResMed I Q3 2019 Investor Presentation | 14 AirTouch F20 Full face mask 85 myAir™ ResMed#15Working with others to raise sleep as a public priority sleepscore verily labs. Consumer tech joint venture with Dr. Oz and Pegasus Capital World's first non- contact sleep tracking mobile app Shows people how they sleep, and how they can improve their sleep Sleep research joint venture with Verily To study the health and financial impacts of untreated sleep apnea Based on research: Develop software solutions to help. identify, diagnose, treat and manage those with OSA ©2019 ResMed I Q3 2019 Investor Presentation | 15 ResMed#16Our Business - Respiratory Care ©2019 ResMed I Q3 2019 Investor Presentation | 16 ResMed#17Respiratory care strategy Changing the lives of COPD patients by bringing new solutions for unmet patient needs WIN IN THE CORE INNOVATE AND EXPAND INTO ADJACENCIES (+) TRANSFORM COPD HEALTHCARE DELIVERY Reach more COPD patients through connected non-invasive ventilation Drive profitable growth in life- support ventilation Grow POC sales through business model innovation Treat patients earlier in COPD disease progression through a connected ecosystem Continue to leverage investments in life support and NIV Further innovate & scale the portable oxygen business model Better prove connected health value propositions Build intelligent therapy solutions enabled by sensor technologies, data analytics, Al and ML with improved patient/care giver engagement Create value propositions in longitudinal care, predict exacerbations, and prevent hospitalization Support new business models & tailored products in emerging growth markets Collaboration - Operating Excellence - Lean Innovation - High Performance Culture - Talent ©2019 ResMed I Q3 2019 Investor Presentation | 17 ResMed#18What is chronic obstructive pulmonary disease (COPD)? COPD is a serious lung disease that over time, makes it hard to breathe Causes include: • smoking & second hand smoke . pollution • occupational exposure to noxious gases • a history of childhood infections (could be a catalyst) genetic inheritance, leading to its onset. ©2019 ResMed I Q3 2019 Investor Presentation | 18 ResMed#19> COPD is a large and growing market . . . COPD is the third leading cause of death worldwide 1 More than 380 million people worldwide are estimated to have COPD 2 - Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil and E. Europe may be well over 100 million 3 • Cost to healthcare systems from COPD is enormous: - Europe: ~€48 billion per year - US: ~$50 billion per year5 • More than 3 million people worldwide die each year due to COPD 6 1World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20 Jul16 2 https://www.ncbi.nlm.nih.gov/pubmed/26755942 3 Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care 4 European Respiratory Society, European Lung White Book http://www.erswhite book.org/chapters/the-economic-burden-of-lung-disease/ accessed 20Jul16 5 Guarascio et al. Dove Med Press, 2013 Jun 17 6 World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20 Jul16 © 2019 ResMed I Q3 2019 Investor Presentation | 19 ResMed#20Respiratory Care: Our point of view People with COPD are not well served by healthcare systems today - - Better solutions are needed for patients, physicians, care providers, and payers •Technology-enabled medical devices will be incorporated within integrated care models to more effectively manage patient needs • Improving outcomes in respiratory care will require solutions that reach the patient much earlier in their disease progression • Digitally-enabled, end-to-end solutions will be key to reaching and supporting the millions of patients with chronic respiratory diseases in emerging markets © 2019 ResMed I Q3 2019 Investor Presentation | 20#21> Full spectrum of solutions for respiratory care High-Flow Therapy AcuCare TM high flow Bilevel Ventilation Portable Oxygen Concentrator Non-invasive Ventilation (NIV) 2 Rasiled TM Mobi™M Life Support Ventilation AirCurve 10 TM Lumis Stellar T TM Astral TM Astral™ with RCM ©2019 ResMed I Q3 2019 Investor Presentation | 21 Patient Acuity ResMed#22Extending connected health solutions to COPD & asthma Acquired Propeller Health in January 2019 Digital therapeutics company providing connected health solutions for people with COPD and asthma Uses sensors with inhalers to track medication usage and provide personal feedback and insights Establishes ResMed as a leading provider of COPD and asthma patient management solutions Enables integration of care through the progression of the disease. UPSTREAM Customers include: gsk Boehringer Ingelheim $$ Patients + $$ ORION NOVARTIS Increased drug adherence and sales Propeller Pharma companies signed represent 90% of long-acting respiratory inhalation drugs ©2019 ResMed I Q3 2019 Investor Presentation | 22 Improved clinical trial speed and enhanced time to market D Patient Acquisition + Health and economic outcomes DOWNSTREAM Payers Anthem. PBMs EXPRESS SCRIPTS Clinical insights and efficiencies Health systems Dignity Health $$ Pharmacies Walgreens Patients + $$ ResMed#23Propeller has demonstrated compelling clinical outcomes i Impact of the Propeller solution tracking inhaler usage and location SABA use over time Symptom free days Healthcare utilization # per day % Events -25% 79 2.0 +32% 75 1.5 -50% 50 50 1.0 25 0.5 Uncontrolled 0.0 COPD 0 50 100 150 Uncontrolled Asthma Drives a decrease in medication Adherence % 59 0 200 0 50 100 150 200 Before After Drives an improvement in Drives a reduction in healthcare utilization QOL QoL: Rescue Inhaler use per day Acute care utilization # times used Events per 100 patient years 1.5 Pre-enrollment 13 12 Post-enrollment +58% 57 1.0 36 -75% 0.5 0.0 Control Intervention 1 Drives an 180 Drives an improvement in improvement in ©2019 ResMed I Q3 2019 Investor Presentation | 23 adherence QOL 6 5 2 0 365 ED + Hosp. ED Hosp. Drives a reduction in healthcare utilization ResMed#24ResMed + Propeller = platform for entire patient journey Total Addressable Market: ~380 million patients¹ Global COPD population COPD progression ResMed Propeller zz 75% of TAM Stage I Stage II 1. Source: https://www.ncbi.nlm.nih.gov/pubmed/26755942 © 2019 ResMed I Q3 2019 Investor Presentation | 24 Increasing severity of disease Self-management & Smoking Cessation Inhaled Medications 20% of TAM Supplementary 02 Ventilation <1% of TAM Stage III Stage IV ResMed#25Our Business - Software as a Service (SaaS) ©2019 ResMed I Q3 2019 Investor Presentation | 25 ResMed#26SaaS strategy - revolutionizing out-of-hospital healthcare Smart ResMed Connected LPC Ecosystem HME Home Health Senior Living Physician Payer Patient Caregiver аио ралот Skilled Nursing Hospice Private Duty Better patient experience. Improved clinical outcomes. Lower overall cost of care. • . Single view of the patient Comprehensive interoperability Care transition, coordination and collaboration Seamless access to information for patients and those who care for them Manage populations across provider / care settings • Data insights to enable better care / better results Connected systems deliver the best outcomes for value-based care ©2019 ResMed I Q3 2019 Investor Presentation | 26 ResMed#27Broad portfolio of out-of-hospital verticals Loved One/ Caregiver છે Physician Patients and Residents $$ Payor Hospital Matrix Care Home Health Hospice Private Skilled Senior Life Plan Duty Nursing Living Community HEALTHCARE +First HEALTHCARE +first brightree. brightree. © 2019 ResMed | Q3 2019 Investor Presentation | 27 Brightree HME Providers ResMed Sleep and RC Products & Solutions ResMed#28History of successful SaaS acquisitions and integrations Company UMB AN ①JAYSEC TECHNOLOGIES Location Halifax, NS Canada Date Key Product Status Aug 2012 U-Sleep Integrated into AirView. Knoxville, TN Feb 2015 GoJaysec Rebranded as GoScripts. CareTouch Denver, CO Jul 2015 Care Touch 360 Rebranded as ResMed ReSupply. brightree® Lawrenceville, GA Feb 2016 Brightree Core Operating as a wholly-owned subsidiary. conduittechnology Girard, PA Jun 2017 MyForms Integrated into Brightree. AllCall Connect Joliet, IL Jul 2017 Brightree ConnectPRO Integrated into Brightree. HEALTHCARE +first MatrixCare Integrated Care. Better Outcomes Springfield, MO Jul 2018 firstHOMECARE Software (EHR) Integrated with Brightree and Matrix Care. Bloomington, MN Nov 2018 Apacheta PARATION Mobile Business Solutions Media, PA Dec 2018 © 2019 ResMed | Q3 2019 Investor Presentation | 28 MatrixCare One Operating as a wholly owned subsidiary. Apacheta ACE (a mobile enterprise Operating as a part of Brightree, with an independent brand. application platform)#29Summary The portfolio is financially attractive on its own and we have leading positions in key segments. ©2019 ResMed I Q3 2019 Investor Presentation | 29 $ Supports growth for existing businesses (HME) and chronic diseases, sleep apnea and COPD in particular. The ecosystem and scale creates our competitive advantage. ResMed#30> Digital Health Technology ©2019 ResMed I Q3 2019 Investor Presentation | 30 ResMed#31Digital health technology supports all of ResMed Purpose: Enable all ResMed businesses to achieve their business objectives by leveraging Healthcare Informatics technology and Advanced Analytics. Sleep Respiratory Care SaaS ↑ ↑↑ ↑ ↑ ↑ ↑ ↑ ↑↑ Digital Health Technology Technology Advanced Analytics © 2019 ResMed I Q3 2019 Investor Presentation | 31 45 ResMed#32Digital health technology strategy MatrixCare AirView™ Integrated Care. Better Outcomes. brightree ९ Connected Health Ecosystem . Innovate for core Sleep and RC business Device connectivity to the cloud - Patient monitoring and management Patient engagement Out-of-Hospital SaaS Ecosystem • • • e Prescribe and Resupply Integrations with our SaaS platforms Accelerating the ResMed value proposition for our customers and patients Data Analytics - The Al Journey Drive better clinical outcomes for patients and business outcomes for providers • Leverage big data to derive meaningful actionable insights using more than 4 billion nights of sleep data • Talented team of data scientists using artificial intelligence and machine learning to improve long-term patient adherence ©2019 ResMed I Q3 2019 Investor Presentation | 32 ResMed#33> Solving for pain points in the physician/provider/patient ecosystem Medical record Physician Provider/HME Physician access to Evolution from Multiple systems paper to increase Increased documentation meaningful electronic record potential for requirements clinical data systems errors ©2019 ResMed I Q3 2019 Investor Presentation | 33 12:0479 Monday, August 29▾ 99 100 points That's a great score Yours we on your way to improving your heat 656 uge hors 69/70) Good as se 1.1 events per hove 1 mask on من Patient Real-time patient engagement ResMed#34Improving outcomes for patients, physicians, and providers. ResMed Data Exchange 85 85 85 brightree. AirView myAir Following the workflow for setting up one patient. Managing one patient or many to compliance. Engaging patients in their therapy. 1 ©2019 ResMed I Q3 2019 Investor Presentation | 34 2 3 ResMed#35Transforming 4+ billion nights of medical data into useful outcomes Global Leader in Cloud-Connected Medical Devices ApneaLink Air Type Ill home sleep testing device ResMed 3rd Party Diagnostics ApneaLink Air DIAGNOSIS AirView™ DIAGNOSTICS AirView™ ActionGroups Air10™ series AirView™ 12 Comp 01011 THERAPY Astral™ with RCM AirMini™ ©2019 ResMed I Q3 2019 Investor Presentation | 35 ResMed 34 10 78 11 8 10 MyAir 85 brightree. MONITORING & MGMT. > PATIENT ENGAGEMENT BILLING & INTEGRATIONS Go Scripts ReSupply Complete Referal and Documentation Softwa 90 ResMed Data Exchange 3rd Party Integrations ResMed#36> Global leadership in digital health AirView™ has over 10 million+ patients 9 million+ 100% cloud connectable devices worldwide 800,000+ diagnostic tests processed in the cloud ~80 million accounts in out-of-hospital care network 84 API calls per second 1.8 million+ patients have from integrators ©2019 ResMed I Q3 2019 Investor Presentation | 36 TM signed up for myAir ResMed#37Financial Results ©2019 ResMed I Q3 2019 Investor Presentation | 37 ResMed#38Key financial results Q3 2019 Diversified revenue by geography & by business Revenue Gross margin Non-GAAP operating profit* Non-GAAP net income* $662.2M +12% (+15% CC) 59.2% +100 bps $182.0M +15% $128.1M Europe, Asia and Other 35% (3)% $0.89 Non-GAAP EPS* (3)% Cash flow from operations $139.6M Free cash flow $124.6M ResMed adjusts for the impact of the amortization of acquired intangibles, deferred revenue fair value adjustment, the impact of U.S. tax reform on income tax expense, acquisition-related expenses, and restructuring-related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. © 2019 ResMed I Q3 2019 Investor Presentation | 38 Masks and Accessories 37% OOH SaaS 12% US, Canada and Latin America 65% Devices 51% ResMed#39Focus on operating excellence and fiscal discipline driving continued improvements in operating leverage ($ in millions) Non-GAAP Operating Profit Margin $750 $500 $250 $- ©2019 ResMed I Q3 2019 Investor Presentation | 39 26.9% 27.4% $665 $591 12% $159 3Q18 15% Non-GAAP Operating Income ■Non-GAAP Revenue $182 3Q19 ResMed#40Track record of disciplined financial growth Revenue ($B) Adjusted EPS $1.6 10% CAGR $2.5 $2.42 9% CAGR $3.65 Quarterly dividend $0.25 8% CAGR $0.37 LTM 3Q14 LTM 3Q19 LTM 3Q14 LTM 3Q19 LTM 3Q14 LTM 3Q19 Fiscal Years ended June 30 ©2019 ResMed I Q3 2019 Investor Presentation | 40 ResMed#41> Proven capital management Capital Deployment Investment for Growth ☐ New Products ☐ Geographic expansion Acquisitions Free Cash Flow returned to Shareholders Last twelve months combined dividend and stock repurchase = 67% of free cash flow Increasing Dividend YTD FY2019 dividend payout ratio of 41% of adjusted net income Dividend per share increased by 6% over prior year Combined dividend and buy-back over rolling 5 years = 65% of free cash flow © 2019 ResMed I Q3 2019 Investor Presentation | 41 ResMed#42> Recognized by Forbes at #1 in category for corporate citizenship. Eliminating unnecessary waste We work to eliminate unnecessary waste in all our systems & processes, such as minimizing our use of natural resources. Minimizing pollution Product stewardship We are minimizing pollution, in particular our non-biodegradable waste to landfill. We design and develop products with reduced impact on the environment through their lifecycle. Responsible compliance We fulfill all relevant and applicable compliance obligations in the countries and communities that we operate in. Increased awareness and continual improvement We drive internal awareness of environmental impacts and monitor our performance through collaboration with others to make continual improvements ? 1. AMERICA'S MOST JUST THE WALL STREET JOURNAL WSJ Recognized by others for leading in this space: Forbes #18 on Forbes & Just Capital's "2019 Just 100”, #1 in Healthcare Equipment and Services #170 on WSJ's 2018 Management Top 250 of the U.S.'s most well-run companies for customers, employees, and investors ©2019 ResMed I Q3 2019 Investor Presentation | 42#43In the last 12 months, we changed more than 14 million lives with our products and improved nearly 80 million more via our out-of-hospital care network Wednesday, January 31- 85 100 points That's a great score! You're well on your way to improving your health 5:58 usage hours 60/70) Adjust mask seal 5.4 events per hour o 3 mask onoff 4/5) 0 日 Our aspiration is to improve 250 million lives in 2025 ResMed#44Why invest? driving long-term shareholder value لحا Market Dynamics • Underpenetrated markets in sleep & COPD • Healthcare costs continue to increase · Focus on improving patient outcomes • Value-based technology solutions Growth & Innovation Global leader in connected health for sleep and respiratory care • Long-term growth opportunities 5,500+ patents and designs1 • 7-8% of revenue 2 invested in R&D Financial Results • Historical revenue and • • profit growth Recurring revenue Operating excellence program Strong track record of disciplined capital deployment 1. Pending and issued patents and designs as of 3/31/2019 ©2019 ResMed I Q3 2019 Investor Presentation | 44 ResMed#45Contact Investor Relations Phone: (858) 836-5971 Email: [email protected] Website: www.investors.resmed.com ©2019 ResMed I Q3 2019 Investor Presentation | 45 ResMed#46> APPENDIX ©2019 ResMed I Q3 2019 Investor Presentation | 46 ResMed#47Market-leading connected health solutions Pioneering innovations and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers AirView™ myAir TM 85 85 100 points 85 121% patient adherence 1. 2. 3. 2014 4. with automated compliance coaching 1 Labor Costs² 159% New Patient 155% Setups³ Hwang, et al., AJRCCM 2017 Munafo, et al. Sleep Breath 2016 Data based on monthly patient setups and compliance rates of DME customers from February March 2015. Historical results for this provider over the stated time Crocker, et al., Abstract CHEST 2016 World's largest study for adherence > 128,000 patients 124% patient adherence with patient engagement4 ©2019 ResMed I Q3 2019 Investor Presentation | 47 ResMed#48Improving adherence to therapy ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Probability on Therapy (%) 100 100% 0 Resupply group (AirView + Brightree) 90 Control group (non-resupply) Time to Drop out (days) + brightree. AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. © 2019 ResMed I Q3 2019 Investor Presentation | 48 ResMed#49Big data analysis drives insights for treatment of central sleep apnea Patients with treatment-emergent central sleep apnea (CSA) are two times more likely to terminate therapy • Opportunity to rethink conventional therapeutic options . • Minimize risk of therapy termination through early diagnosis • Regularly monitor patients to support adherence to treatment CHEST Journal Analysis of ~200k CSA patients 100 50 22% increase in adherence CMS adherence on CPAP prior to switching 62.7% CMS adherence after switching to ASV 76.6% • Switching from therapy CPAP to ASV improved relative adherence by 22% Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep © 2019 ResMed I Q3 2019 Investor Presentation | 49 ResMed#50Reducing Mortality with PAP Therapy U.S. multicenter, population-based cohort study • Positive airway pressure therapy associated with a 62% lower risk of all-cause mortality • Death rate was twice as high for persons who did not receive positive airway pressure therapy - (24.7 vs 12.8 deaths per 1000 person years, p = 0.03) Proportion Surviving, % 100 90- 80 70- 60 0 Sleep Heart Health Study HR, 0.38 (95% CI, 0.18-0.81) PAP prescribed PAP not prescribed 5 10 15 20 Time, y Lisan et al., Association of PAP prescription with mortality in patients with obesity and severe OSA. The Sleep Heart Health Study, JAMA Otolaryngol Head Neck Surg 2019 ©2019 ResMed I Q3 2019 Investor Presentation | 50 ResMed#51Opportunity to shift care from hospital to home Healthcare costs are on the rise Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT) Reduces hospitalization and mortality by 51% - - Increases time to hospital readmission or death by ~90 days. JAMAⓇ The Journal of the American Medical Association Admission-free Survival % 100 80 60 60 60 40 20 Admission-free survival by treatment arm over one year Adjusted hazard ratio, 0.49 (0.31-0.77); P=.002 Home Oxygen Plus Home NIV Home Oxygen Alone • Combination of HOT with NIV reduced hospital readmissions by 58.3% Combination of therapies provided improved patient quality of life and saved >$50k per quality of life adjusted year 0 0 2 4 6 8 10 12 Time (months) 1 P. Murphy et al., Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial, JAMA Published online May 21, 2017. doi:10.1001/jama.2017.4451. © 2019 ResMed I Q3 2019 Investor Presentation | 51 ResMed